Development of a Video Game for the Improvement of Outcomes in Stem Cell Transplant Survivors

Sponsor
M.D. Anderson Cancer Center (Other)
Overall Status
Recruiting
CT.gov ID
NCT01608152
Collaborator
National Cancer Institute (NCI) (NIH)
40
Enrollment
1
Location
106.3
Anticipated Duration (Months)
0.4
Patients Per Site Per Month

Study Details

Study Description

Brief Summary

This trial collects feedback from patients to develop a video game in improving the outcomes in stem cell transplant survivors. A video game may help to improve health behaviors for leukemia or lymphoma patients after stem cell transplant.

Condition or DiseaseIntervention/TreatmentPhase
  • Behavioral: Focus Group
  • Other: Internet-Based Intervention
  • Behavioral: Interview

Detailed Description

PRIMARY OBJECTIVES:
  1. Develop a prototype intervention electronic game that implements a baseline testable feature set, including features for social networking within a virtual game space, managing an intermittent mediated reward cycle, goal setting and tracking, and collaborative problem solving.

  2. Evaluate the technical merit, feasibility, user perception and acceptance of the prototype system with adolescents and young adults (AYAs) allogeneic hematopoietic stem cell transplantation (HSCTs) patients in recovery.

OUTLINE: Patients are assigned to 1 of 2 groups.

GROUP I: Patients attend a focus group for up to 1.5 hours and provide feedback on design elements, specific desirable features, and preferences for the initial prototype.

GROUP II: Patients have access to the game for 3 weeks and then provide feedback on problems or questions regarding the use of the prototype.

Study Design

Study Type:
Observational
Anticipated Enrollment :
40 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
Using Game Mechanics to Improve Outcomes Among Stem Cell Transplant Survivors
Actual Study Start Date :
Feb 20, 2013
Anticipated Primary Completion Date :
Dec 31, 2021
Anticipated Study Completion Date :
Dec 31, 2021

Arms and Interventions

ArmIntervention/Treatment
Group I (focus group)

Patients attend a focus group for up to 1.5 hours and provide feedback on design elements, specific desirable features, and preferences for the initial prototype.

Behavioral: Focus Group
Attend a focus group

Group II (access to the game)

Patients have access to the game for 3 weeks and then provide feedback on problems or questions regarding the use of the prototype.

Other: Internet-Based Intervention
Have access to the game

Behavioral: Interview
1 week after the 3-week period ends, interview conducted over the phone or at a clinic visit.

Outcome Measures

Primary Outcome Measures

  1. Feasibility of electronic game intervention [4 weeks]

    Primary feasibility benchmark based on responses to questions regarding users' perceptions of the technology. If 75% of respondents have a mean score reflecting positive responses (e.g., strongly agree or agree) to each of the 7 constructs related to users' perceptions, as described above, then feasibility benchmark met. Responses to open-ended questions analyzed qualitatively using Atlas.ti software. Responses to individual questions evaluated to look for common themes, and findings used to inform future development of the prototype.

Eligibility Criteria

Criteria

Ages Eligible for Study:
15 Years to 29 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  1. Age 15-29 years
  • Diagnosis of leukemia or lymphoma

  • Able to speak, read and write English

  • First time allogeneic stem cell transplant recipient

Exclusion Criteria:
  • Unable to participate in the study due to language, vision, cognitive or other difficulties, as advised by their health care provider(s)

Contacts and Locations

Locations

SiteCityStateCountryPostal Code
1M D Anderson Cancer CenterHoustonTexasUnited States77030

Sponsors and Collaborators

  • M.D. Anderson Cancer Center
  • National Cancer Institute (NCI)

Investigators

  • Principal Investigator: Susan K Peterson, M.D. Anderson Cancer Center

Study Documents (Full-Text)

None provided.

More Information

Additional Information:

Publications

None provided.
Responsible Party:
M.D. Anderson Cancer Center
ClinicalTrials.gov Identifier:
NCT01608152
Other Study ID Numbers:
  • 2012-0362
  • NCI-2020-00573
  • 2012-0362
  • P30CA016672
  • R41CA168107
First Posted:
May 30, 2012
Last Update Posted:
Oct 21, 2021
Last Verified:
Oct 1, 2021
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by M.D. Anderson Cancer Center
Additional relevant MeSH terms:

Study Results

No Results Posted as of Oct 21, 2021